Jasper Therapeutics, Inc.
JSPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14,391 | $21,196 | $16,157 | $19,772 |
| G&A Expenses | $4,775 | $5,880 | $5,645 | $5,513 |
| SG&A Expenses | $4,775 | $5,880 | $5,645 | $5,513 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $19,166 | $27,076 | $21,802 | $25,285 |
| Operating Income | -$19,166 | -$27,076 | -$21,802 | -$25,285 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $430 | $353 | $561 | $964 |
| Pre-Tax Income | -$18,736 | -$26,723 | -$21,241 | -$24,321 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18,736 | -$26,723 | -$21,241 | -$24,321 |
| % Margin | – | – | – | – |
| EPS | -1.13 | -1.74 | -1.41 | -1.62 |
| % Growth | 35.1% | -23.4% | 13% | – |
| EPS Diluted | -1.13 | -1.74 | -1.41 | -1.62 |
| Weighted Avg Shares Out | 16,580 | 15,333 | 15,022 | 15,008 |
| Weighted Avg Shares Out Dil | 16,636 | 15,334 | 15,022 | 15,008 |
| Supplemental Information | – | – | – | – |
| Interest Income | $342 | $437 | $624 | $938 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $229 | $258 | $279 | $245 |
| EBITDA | -$18,507 | -$26,818 | -$21,523 | -$25,040 |
| % Margin | – | – | – | – |